

GW788388

Catalog No: tcsc0254



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

452342-67-5

Formula:

$C_{25}H_{23}N_5O_2$

Pathway:

TGF-beta/Smad

Target:

TGF- β Receptor

Form:

White to gray (Solid)

Purity / Grade:

97.61%

Solubility:

DMSO : ≥ 48 mg/mL (112.81 mM)

Storage Instruction:

Storage temp. 2-8°C

Observed Molecular Weight:

425.48

References

[1]. Petersen M, et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. *Kidney Int*, 2008, 73(6), 705-715. [2]. Tan SM, et al. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. *Am J Physiol Heart Circ Physiol*, 2010, 298(5), H1415-1425. [3]. Gellibert F, et al. Discovery of 4-(4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. *J Med Chem*. 2006, 49

Notes


Biological Activity: GW788388 is a potent and selective inhibitor of ALK5 with IC₅₀ of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor. **IC₅₀ & Target:** IC₅₀: 18 nM (ALK5) **In Vivo:** GW788388 given orally for 5 weeks significantly reduces renal fibrosis and decreased the mRNA levels of key mediators of extracellular matrix deposition in kidneys in db/db mice[1]. GW788388 (50 mg/kg/day, p.o.) significantly attenuates systolic dysfunction in the MI animals, together with the attenuation of the activated (phosphorylated) Smad2 (P < 0.01), α-smooth muscle actin (P < 0.001), and collagen I (P < 0.05) in the noninfarct zone of MI rats[2]. GW788388 reduces the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). GW788388 significantly reduces the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis[3].

Product Description

GW788388 is a potent and selective inhibitor of **ALK5** with **IC₅₀** of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.

IC₅₀ & Target: IC₅₀: 18 nM (ALK5)

In Vivo: GW788388 given orally for 5 weeks significantly reduces renal fibrosis and decreased the mRNA levels of key mediators of extracellular matrix deposition in kidneys in db/db mice^[1]. GW788388 (50 mg/kg/day, p.o.) significantly attenuates systolic dysfunction in the MI animals, together with the attenuation of the activated (phosphorylated) Smad2 (P [2]. GW788388 reduces the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). GW788388 significantly reduces the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!